MarketPulse

AACR Annual Meeting

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion's AI Platform Unlocks Novel Antigen Source for Glioblastoma Vaccines

Evaxion's AI-Immunology platform identifies endogenous retroviruses as glioblastoma vaccine targets, addressing mutational burden challenges. Results presented at AACR in April 2026.
EVAXpersonalized medicinecancer immunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Cogent Biosciences, Inc.

Cogent Biosciences Showcases Dual Pipeline Advances at AACR 2026 Meeting

Cogent Biosciences highlights preclinical data for KRAS and HER2 inhibitors at AACR 2026, with IND submission planned for CGT1263.
COGTIND submissionAACR Annual Meeting
BenzingaBenzinga··Vandana Singh

Tempus AI Surges on AACR Data Windfall Despite Jefferies Skepticism

Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.
TEMcolorectal cancerprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mestag's MST-0312 Advances to AACR Stage Ahead of Mid-2026 Clinical Launch

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.
JNJMRKsolid tumorsbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Foghorn Therapeutics to Showcase Epigenetic Cancer Targets at 2026 AACR Meeting

Foghorn Therapeutics will present preclinical data on SMARCA2 and epigenetic degrader programs at AACR 2026, advancing pipeline with Eli Lilly partnership.
LLYFHTXcancer treatmentAACR Annual Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's AP3 Platform Shows Promise: ACR-368 Synergies Highlighted at AACR 2026

Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.
ACRVendometrial cancerAACR Annual Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC